Warfarin and Antiplatelet Vascular Evaluation
Peripheral Vascular Diseases, Cardiovascular Diseases
About this trial
This is an interventional prevention trial for Peripheral Vascular Diseases focused on measuring Warfarin and Antiplatelet Vascular Evaluation, Peripheral vascular disease, Atherosclerosis, cardiovascular events, Ischemia, oral anticoagulants, low ankle-brachial index, moderate intensity warfarin, International normalized ratio [INR]
Eligibility Criteria
Inclusion Criteria: Intermittent claudication with objective evidence of PVD (e.g. ankle-brachial index [ABI] < 0.90) Ischemic rest pain of the lower limbs Ischemic non-healing ulcers or focal gangrene Amputation for vascular causes Previous peripheral vascular revascularization (angioplasty or bypass surgery) Blue toe syndrome Other significant peripheral arterial disease (e.g. carotid stenosis) Vascular disease and evidence of asymptomatic peripheral arterial disease [PAD] (i.e. ABI < 0.90) Exclusion Criteria: Temporary: Potential subjects will be temporarily excluded if they need to undergo: vascular diagnostic (angiography) or interventional procedures (arterial bypass graft surgery or angioplasty); or limb amputation for vascular insufficiency. Permanent: Subjects will be excluded for the following: active bleeding or high risk bleeding; clear indication for long-term warfarin use (i.e. atrial fibrillation); previous allergy or intolerance to warfarin; stroke in the last 6 months; renal failure requiring dialysis; known significant abdominal aortic or cerebral aneurysm; peripheral arterial aneurysms (iliac or femoral) without evidence of lower limb ischemia; significant liver disease (i.e. cirrhosis); cancer with a life expectancy < 6 months; anticipated non-adherence to warfarin; excessive alcohol use; pregnancy or planning to become pregnant; or failure to provide informed consent.
Sites / Locations
- Population Health Research Institute, McMaster University